The Changing Face of Advanced Prostate Cancer 2022 Webcast (2022)

This is an ongoing course on advanced prostate cancer at the annual AUA since 2012 and the changes over these 10 years have been nothing less than breathtaking! In the early years, it was all about metastatic castrate resistant prostate cancer (CRPC) with multiple new therapeutic advances starting in 2010 with novel immunotherapy, AR targeted therapies and bone-targeted agents. Later, the course expanded to cover hormone sensitive (HS) advanced disease due to the new data on systemic chemotherapy and AR-directed therapy extending survival in new M1 patients. In 2017, the topic of non-metastatic CRPC (M0 CRPC) was added due to emerging data on use of novel oral hormonal therapies. In 2019 before COVID, the course expanded information on HS new M1 disease with emerging data that four novel therapeutic strategies that all improved survival for men with new metastatic prostate cancer. Some may have argued that the value of the course for urologists was a stretch back in 2012 because of the belief, by some physicians, that metastatic CRPC should be managed only by medical oncologists. However, over the last few years; the course is even more relevant to practicing urologists as most M0 CRPC and virtually all new M1 HS patients are initially managed by urologists. Using a case based and multi-disciplinary format, we will continue to push the boundaries of knowledge to urologists and their teams in covering this new toolbox of novel therapies. In addition, we will cover the latest advance in lutetium prostate-specific membrane antigen (PSMA) 617 (VISION and Thera-P trials), and the ACIS and the NGS update (ipatasertib). Finally, bi-specific and tri-specific antibodies are emerging, and will be covered in 2022. It truly has been an honor and pleasure to present this constantly evolving course on advanced prostate cancer and celebrate the 10th anniversary of this ongoing educational exchange.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

Astellas
AstraZeneca
Exact Sciences
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.
Pfizer, Inc.
Sanofi Genzyme

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners and Physician Assistants)

Learning Objectives

At the conclusion of this course, participants will be able to:

  1. Identify and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be able to offer additional therapies that extend survival.
  2. Recognize high volume new M1 prostate cancer to be able to refer to a genitourinary (GU) medical oncologist for systemic chemotherapy.
  3. Diagnose M0 metastatic CRPC and educate patients about using novel oral AR targeted therapeutics added to traditional ADT as a way to improve their patient's overall and radiographic progression-free survival.
  4. Identify the differences between these AR targeted oral agents and to educate patients about side effects and toxicities.
  5. Describe the latest phase III randomized control trial (RCT) results for new therapies in M1 CRPC.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
05/14/2022
Course expires: 
05/14/2023
Rating: 
0

Education Council Disclosures

 Education Council Disclosures 2021

COI Review Work Group Disclosures

 COI Review Work Group Disclosures 2021

All relevant financial relationships have been mitigated. 

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Judd Moul, MD,FACS

has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Blue Earth Diagnostics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tolmar;.
has a financial relationship (Health Publishing (Oncology)) with Up to Date;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bayer;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Exosome Dx ;.
has a financial relationship (Other (Oncology)) with Best Doctors;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Dendreon;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Ferring;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Theralogix;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Sanofi-Aventis;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Genomic Health;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Astellas;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Janssen- J and J;.
Faculty(s)

Lawrence Karsh, MD

has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Hinova;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Cepheid ;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Arivan Research;.
has a financial relationship (Scientific Study or Trial (Oncology)) with FKD;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Nymox ;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Augmenix ;.
has a financial relationship (Consultant or Advisor (Oncology)) with Clovis;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Bristol Myers Squibb;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Epizyme;.
has a financial relationship (Scientific Study or Trial (Oncology)) with QED;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Tavanta;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Genetech/Hoffman;.
has a financial relationship (Consultant or Advisor (Oncology)) with EMD Serono;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Siemans;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Urogen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant ;.
has a financial relationship (Investment Interest (Oncology)) with 3D Biopsy ;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Precision Med;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Bayer;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Exelexis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astra-Zeneca;.
has a financial relationship (Consultant or Advisor (Oncology)) with Kiadis;.
has a financial relationship (Consultant or Advisor (Oncology)) with UroGPO;.
has a financial relationship (Scientific Study or Trial (Oncology)) with NeoGenomic Laboratories;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with BioXcel;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with UROGPO;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Vaxiion;.
has a financial relationship (Consultant or Advisor (Oncology)) with OPKO;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Astellas;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tolmar;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Merck;.
has a financial relationship (Consultant or Advisor (Oncology)) with ABBVIE;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Veru Pharmaceuticals;.
has a financial relationship (Consultant or Advisor (Oncology)) with GenomeDx BIosciences ;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Nucleix ;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with CUSP;.
has a financial relationship (Consultant or Advisor (Oncology)) with Arivan Research;.
has a financial relationship (Consultant or Advisor (General Urology)) with Swan Valley Medical;.
has a financial relationship (Consultant or Advisor (Oncology)) with Precision Biopsy ;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myriad Genetics;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Exact Sciences;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Sesen;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Genomic Health;.
has a financial relationship (Consultant or Advisor (Oncology)) with Boston Scientific;.
has a financial relationship (Consultant or Advisor (Oncology)) with Medivation;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Minomic ;.

Alicia Morgans, MD, MPH

has a financial relationship (Consultant or Advisor (General Urology)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Progenics ;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Astra Zeneca;.
has a financial relationship (Consultant or Advisor (General Urology)) with Novartis;.
has a financial relationship (Consultant or Advisor (General Urology)) with BMS;.
has a financial relationship (Consultant or Advisor (Oncology)) with Clovis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myriad;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Bayer;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Genetech;.
has a financial relationship (Consultant or Advisor (General Urology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (General Urology)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Lantheus;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Sanofi;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Genetech;.
has a financial relationship (Consultant or Advisor (General Urology)) with Myovant;.
has a financial relationship (Consultant or Advisor (Oncology)) with Telix;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Advanced Accelerator Applications;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Astellas;.
has a financial relationship (Consultant or Advisor (Oncology)) with Advanced Accelerator Applications;.
has a financial relationship (Consultant or Advisor (General Urology)) with Merck;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by viewing the webcast, completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2022
Expiration Date: May, 2023

ACCREDIDATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY:

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group. 
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning 
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES

DISCLAIMER:

 The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

CONSENT TO USE OF PHOTOGRAPHIC IMAGES:

Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

REPRODUCTION PERMISSION:

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

SPECIAL ASSISTANCE/ DIETARY NEEDS:

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.